title: [Radionuclide renoscintigraphy for the evaluation of nephroprotective action of acetylcysteine].
abstract: Radionuclide renoscintigraphy was used to evaluate efficiency of nephroprotection by N- acetylcholine in 36 patients subjected to coronaroangiography (CAG). The patients were randomly allocated to 2 groups, one undergoing CAG without nephroprotection, the other CAG in combination with N-acetylcholine nephroprotector. Dynamic radionuclide renoscintigraphy with 99m Tc-dtpa was performed before and 2-3 days after CAG; the results were used to estimate filtration and evacuation efficiency of the kidneys. Patients of group 1 showed negative dynamics of the renal function following CAG including decreased mean glomerular filtration rate and slowed down blood clearance. Mean half-time of 99mTc elimination from the pelvicalyceal system and parenchyma of the left kidney as well as its cortical retention index in bot kidneys increased. The filtration activity of the kidneys did not significantly change after CAF in patients of group 2; it was slightly impaired only in 5 (28%) of them. More patients suffered deterioration of 99mTc elimination but on the whole changes in the evacuation activity of both parenchyma and pelvicalyceal system were statistically insignificant. It is concluded that acetylcholine has nephroprotective action in patients subjected to radionuclide renoscintigraphy.
authors.forename: Zh V
authors.initials: ZhV
authors.lastname: Vesnina
authors.forename: E V
authors.initials: EV
authors.lastname: Rybal'chenko
authors.forename: A M
authors.initials: AM
authors.lastname: Guliaev
authors.forename: Iu B
authors.initials: IuB
authors.lastname: Lishmanov
mesh_terms: D000111:Acetylcysteine / Q000008:administration & dosage / Q000627:therapeutic use*; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D016166:Free Radical Scavengers / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D007472:Iohexol / Q000009:adverse effects / Q000031:analogs & derivatives; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D051437:Renal Insufficiency / Q000139:chemically induced / Q000000981:diagnostic imaging* / Q000517:prevention & control; D016284:Technetium Tc 99m Pentetate; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media; D016166:Free Radical Scavengers; D019275:Radiopharmaceuticals; C093233:iobitridol; D007472:Iohexol; D016284:Technetium Tc 99m Pentetate; D000111:Acetylcysteine